Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective.

Lung cancer (Amsterdam, Netherlands)·2026

Same author

Virtual Evaluation of Hematoxylin & Eosin via Digital Pathology Survey (VEED) Project: Results from a Non-Inferiority Study of a Tabs-Based Staining Method.

Diagnostics (Basel, Switzerland)·2026

Same author

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.

Molecular diagnosis & therapy·2026

Same author

Supernatant: What's in a name?

Cancer cytopathology·2026

Same author

Advances in early-stage lung cancer patients: from preanalytics to molecular analysis.

Critical reviews in oncology/hematology·2026

Same author

Toward Precision Electrochemical Sensing of CFTR Function in Cystic Fibrosis Models.

Analytical chemistry·2026

Same journal

Architectural Subtyping of Three-Dimensional Cell Groups in Bethesda III Thyroid Cytology: Distinguishing Spherules From Their Mimickers.

Cytopathology : official journal of the British Society for Clinical Cytology·2026

Same journal

Cervical Cytokine Profile in High-Grade Squamous Intraepithelial Lesions.

Cytopathology : official journal of the British Society for Clinical Cytology·2026

Same journal

COVID-19's Shadow: The Effect of COVID-19 on Cytopathology Specimens Received at an Academic Laboratory in Central South Africa.

Cytopathology : official journal of the British Society for Clinical Cytology·2026

Same journal

Psammoma Bodies in Cervical Liquid-Based Cytology of a Kyleena User.

Cytopathology : official journal of the British Society for Clinical Cytology·2026

Same journal

The Diagnostic Yield of Fine Needle Aspiration and Biopsy Needles According to Needle Passes Number in Diagnosing Pancreatic Adenocarcinoma.

Cytopathology : official journal of the British Society for Clinical Cytology·2026

Same journal

Challenges in Diagnosing Isolated Rib Metastasis From Low-Grade Endometrial Carcinoma: Utility of USG-FNAC and Molecular Characterisation.

Cytopathology : official journal of the British Society for Clinical Cytology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 13, 2025

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

Liquid Biopsy in Solid Tumours: An Overview.

Pasquale Pisapia¹, Antonino Iaccarino², Giancarlo Troncone¹

¹Department of Public Health, University of Naples Federico II, Naples, Italy.

Cytopathology : Official Journal of the British Society for Clinical Cytology

|April 12, 2025

Summary

This summary is machine-generated.

Liquid biopsy using circulating tumor DNA (ctDNA) offers a noninvasive method for cancer molecular profiling. This approach aids in treatment decisions, monitoring minimal residual disease, and detecting early-stage cancers.

Keywords:

NGS ctDNA liquid biopsy molecular oncology molecular pathology

More Related Videos

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Published on: January 13, 2023

Related Experiment Videos

Last Updated: Jun 13, 2025

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Published on: January 13, 2023

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

Personalized and precision medicine have transformed cancer care.
The increasing number of biomarkers necessitates efficient molecular profiling tests.
Liquid biopsy, especially circulating tumor DNA (ctDNA), addresses the need for noninvasive molecular profiling.

Purpose of the Study:

To review the clinical utility of ctDNA analysis in solid tumors.
To highlight the advantages of ctDNA analysis over traditional tissue biopsies.
To explore the role of ctDNA in guiding cancer treatment and monitoring.

Main Methods:

Systematic review of current evidence on ctDNA analysis in solid tumors.
Analysis of studies focusing on the clinical applications of ctDNA.
Evaluation of ctDNA's role in treatment selection, MRD monitoring, and early detection.

Main Results:

ctDNA analysis provides a noninvasive alternative to tissue biopsy, crucial when samples are scarce.
It guides treatment decisions by assessing response or resistance to targeted therapies.
ctDNA aids in monitoring minimal residual disease (MRD) and facilitates early cancer detection and interception.

Conclusions:

ctDNA analysis is a valuable tool in personalized cancer medicine, offering significant advantages over tissue-based methods.
It plays a critical role in treatment selection, disease monitoring, and early cancer detection.
Understanding tumor heterogeneity through ctDNA analysis is key to overcoming therapeutic resistance.